Cellworks

Executive Summary

Cellworks is a private US biotechnology company headquartered in San Francisco, founded in 2005. It has developed a proprietary biosimulation platform that combines computational biology, mechanistic modeling, and artificial intelligence to personalize cancer therapy. By predicting how individual patients will respond to FDA-approved drugs and drug combinations, Cellworks aims to improve clinical decision-making and streamline drug development in oncology. The platform analyzes the unique disease biology of each patient, enabling physicians to select the most effective treatment regimens while avoiding ineffective therapies. This in silico approach has the potential to reduce trial-and-error prescribing, lower healthcare costs, and improve patient outcomes. While Cellworks has maintained a low profile since its founding, its technology addresses a critical unmet need in precision oncology: the ability to model complex biological systems to predict therapeutic responses. The company has not publicly disclosed funding rounds or clinical partnerships, but the growing adoption of AI-driven drug discovery and personalized medicine suggests significant opportunity. If Cellworks can demonstrate clinical validation through collaborations or peer-reviewed studies, it could emerge as a key player in the digital therapeutics space. However, given the lack of recent public milestones, near-term catalysts remain uncertain.

Upcoming Catalysts (preview)

• Q3 2026Announcement of strategic partnership with a major pharmaceutical company40% success
• Q2 2026Publication of clinical validation study results in a peer-reviewed journal60% success
• Q4 2026Series C funding round led by healthcare-focused venture capital50% success